Trypanosoma cruzi Type I nitroreductase (TcNTR)

Trypanosoma cruzi Type I nitroreductase (TcNTR) is a mitochondrial, oxygen-insensitive, flavin mononucleotide (FMN)-binding enzyme that plays a critical role in the metabolism of nitroheterocyclic compounds (Wilkinson et al., 2008). Unlike mammalian nitroreductases, which are typically oxygen-sensitive (Type II), TcNTR catalyzes the two-electron reduction of nitro groups even in the presence of oxygen, preventing the formation of superoxide radicals and instead producing toxic hydroxylamine derivatives (Hall & Wilkinson, 2012). This enzyme is the primary activator of the front-line Chagas disease drugs, benznidazole and nifurtimox, converting these prodrugs into reactive intermediates that cause extensive DNA damage and protein adducts within the parasite (Medscape, 2023). Loss or downregulation of TcNTR is a major mechanism of drug resistance in T. cruzi, making it a focal point for monitoring treatment efficacy and developing next-generation trypanocidal agents (Wilkinson et al., 2008). Its absence in human hosts provides a basis for the selective toxicity of nitroheterocyclic therapy, although the systemic side effects of the resulting metabolites remain a clinical challenge (Hall & Wilkinson, 2012).

Other names

Oxygen-insensitive nitroreductaseNADH-dependent nitroreductaseTcNTR1NTR

TcNTR mediates the reductive activation of nitro-containing prodrugs through a series of two-electron transfers, bypassing the production of superoxide radicals and generating toxic reactive intermediates such as hydroxylamines and nitrenium ions that damage parasite DNA and proteins (Wilkinson et al., 2008; Hall & Wilkinson, 2012).